Posted by: Janet Reid on: 20 May, 2016

Trial: REVascularisation for Ischaemic VEntricular Dysfunction (REVIVED-BCIS2)
Details: This randomised controlled trial is designed to evaluate the whether percutaneous coronary intervention (in combination with Optimal Medical Therapy [OMT]) can improve event free survival in patients with sever ischaemic cardiomyopathy, compared to treatment with OMT alone. Patients with poor left ventricular function (EF<35%) and extensive coronary artery disease will be eligible for inclusion, provided they have evidence of viable myocardium. The primary endpoint is all cause death or hospitalisation due to heart failure. Patients will be followed up for at least 2 years (range 2-5 years). The trial is sponsored by King's College London, funded by the National Institute for Health Research (HTA) and overseen by an independent Trial Steering Committee. REVIVED represents a unique collaboration between heart failure and interventional cardiology, a feature that will be central to successful delivery of the trial and also serve as a model for how these patients may be managed in the future. There will be heart failure and intervention leads at each participating centre, while the study group includes past and current presidents of BCIS and chairs of BSH. More details: see the trial website. Interest from new sites is welcome. Please get in touch with the Trial Manager if you are interested in participating or would like more information. Chief Investigator: Divaka Perera, St Thomas' Hospital Campus, KCL ( Trial Manager: Richard Evans, Clinical Trials Unit, LSHTM (

Posted in:

The sidebar will be back soon.